Elutia Faces Nasdaq Delisting After Stock Sinks Below $1.00
ELUT sits 70% above its 52-week low of $0.5 on light trading volume (0.1× avg).
Summary
Elutia received a Nasdaq delisting notice on August 6, 2026, after its stock price fell below $1.00 for 30 consecutive business days. The company has until February 2, 2027, to regain compliance, likely through a reverse stock split.
Key Events · Legal and Risk Events · ELUT
-
Nasdaq Delisting Notice Received
On August 6, 2026, Elutia was notified that its stock had closed below $1.00 for 30 consecutive business days, violating Nasdaq's minimum bid price rule.
-
180-Day Compliance Period
The company has until February 2, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
-
Reverse Split Likely Required
If compliance is not achieved in the initial period, Elutia may qualify for an additional 180 days by committing to a reverse stock split, which would reduce share count but could further pressure the stock.
-
Financial Distress Context
The delisting notice follows a Q1 2026 net loss of $7.47 million and increased cash burn, and the recent sale of the SimpliDerm business for up to $11 million to raise capital.
Analysis · ELUT · Life Sciences
After trading below $1.00 for 30 consecutive days, Elutia has received a Nasdaq delisting notice. The company now has 180 days — until February 2, 2027 — to regain compliance, most likely through a reverse stock split. Should it fail, a move to over-the-counter markets would severely limit liquidity and institutional access. This development arrives amid a wider net loss and increased cash burn reported in Q1 2026, and just weeks after the sale of its SimpliDerm business for up to $11 million to shore up finances. The delisting risk compounds existing financial distress and raises the stakes for the company's turnaround efforts.
At the time of this filing, ELUT was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.6M. The 52-week trading range was $0.50 to $2.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.